(Q34514945)

2 August 2017

title

Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. (English)

1 reference

2 August 2017

0 references

Zacharowski K

1

1 reference

2 August 2017

Blackburn B

series ordinal

2

1 reference

2 August 2017

Thiemermann C

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

European Journal of Pharmacology

2 August 2017

published in

1 reference

2 August 2017

volume

418

1 reference

2 August 2017

issue

1-2

1 reference

2 August 2017

page(s)

105-110

1 reference

Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

The Prognostic Value of Serum Troponin T in Unstable Angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

It's time for a change to a troponin standard

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Non-invasive assessment of perioperative myocardial cell damage by circulating cardiac troponin T

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Diagnostic performance and prognostic value of serum troponin T in suspected acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Effect of antilipolytic therapy on ST segment elevation during myocardial ischaemia in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Initial metabolic and hormonal response to acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Selective activation of the prostanoid EP(3) receptor reduces myocardial infarct size in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Endotoxin induces a second window of protection in the rat heart as determined by using p-nitro-blue tetrazolium staining, cardiac troponin T release, and histology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900920-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(01)00920-7

1 reference

2 August 2017

1 reference